Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Discovery of HZ-L105, a Next Generation of Bcl-2 Inhibitor, Overcomes Bcl-2 Mutation and Exhibits Superior Antitumor Activity

Xingguo Liu, Yang Lou, Yizhe Wu, Mingbo Su, Anhui Gao, Jinglai Huang, Haiyan Yang, Li Zhong, Xinglu Zhou

Blood (2022) 140 (Supplement 1): 7798–7799.

https://doi.org/10.1182/blood-2022-166997

Published: 2022

Journal Articles

Discovery and Preclinical Study of Novel BTK Degrader HZ-Q1060

Xingguo Liu, Yubo Zhou, Yizhe Wu, Xiaomin Luo, Jiangfeng Xie, Xinxin Jin, Haiyan Yang, Li Jia, Xinglu Zhou

Blood (2022) 140 (Supplement 1): 4942.

https://doi.org/10.1182/blood-2022-167308

Published: 2022

Journal Articles

Dual CK1ε/PI3Kδ Inhibitor HZ-H08905, Exhibits As a Potential Therapeutic Strategy for Hematologic Malignancies

Juying Wei, Wenjuan Yu, Hongyan Tong, Min Yang, Miao Hu, Xingguo Liu, Yizhe Wu, Xinglu Zhou, Jie Jin

Blood (2022) 140 (Supplement 1): 12065.

https://doi.org/10.1182/blood-2022-165195

Published: 2022

Journal Articles

HZ-a-018 Is a Highly Selective and Potent BTK Inhibitor with CNS-Penetrating Profile for Central Nervous System Lymphoma

Zhuang Kang, Feng Chen, Yi Lin, Xianggui Yuan, Xi Chen, Wenbin Qian, Haiyan Yang, Miao Hu, Xingguo Liu, Xinglu Zhou, Wenbin Li

Blood (2022) 140 (Supplement 1): 12064.

https://doi.org/10.1182/blood-2022-166776

Published: 2022

Journal Articles

HZ-R061, a Selective STAT3 Degrader with Activity in Preclinical Model of Hematologic Malignances

Yizhe Wu, Xingguo Liu, Xinxin Jin, Jiangfeng Xie, Haiyan Yang, Xinglu Zhou

Blood (2022) 140 (Supplement 1): 7818.

https://doi.org/10.1182/blood-2022-167261

Published: 2022